02:46 PM EDT, 03/12/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) shares were down 9% in recent Tuesday trading after a new analysis of the company's sotagliflozin found similar effect on subjects enrolled in a phase 3 clinical trial and a subset of patients in the study.

A post hoc analysis of the trial found that sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in patients with type 1 diabetes and chronic kidney disease as compared to the total subject population.

The company plans to resubmit the drug for approval as an adjunct to insulin therapy. The new drug application is planned for mid-year, the company said Monday.

Price: 2.55, Change: -0.26, Percent Change: -9.31